[
  {
    "token_count": 125,
    "subprompt": "If you have been caught in the legal trap of a domestic violence case then it can snatch your employment, your home and any chance of living a normal life in the future. So contact an efficient domestic violence lawyer Colorado immediately and get the best solution for your problems. For further information please visit out website\n\nNeon Therapeutics Files for $100 Million IPO for Immuno-Oncology Pipeline\n\n\n\nNeon Therapeutics (Proposed Nasdaq: NTGN) has filed for a $100 million initial public offering to fund clinical development of its neoantigen program. Neoantigens result from",
    "output": " the process of somatic mutation in cancer cells. Neoantigens are unique to each patient and are the target of the immune system. Neoantigens are the basis of the company\u2019s immunotherapy platform. Neoantigens are the target of the immune system. Neoantigens are the basis of the company\u2019s immunotherapy platform. Neoantigens are the target of the immune system. Neoantigens are the basis of the company\u2019s immunotherapy platform. Neoantigens are the target of the immune system. Neoantigens are the basis of the company\u2019s immunotherapy platform. Neoantigens are the target of the immune system. Neoantigens are the basis of the company\u2019s immunotherapy platform. Neoantigens are the target of the immune system. Neoantigens are the basis of the company\u2019s immunotherapy platform. Neoantigens are the target of the immune system. Neoantigens are the basis of the company\u2019s immunotherapy platform. Neoantigens are the target of the immune system. Neoantigens are the basis of the company\u2019s immunotherapy platform. Neoantigens are the target of the immune system. Neoantigens are the basis of the company\u2019s immunotherapy platform. Neoantigens are the target of the immune system. Neoantigens are the basis of the company\u2019s immunotherapy platform. Neoantigens are the target of the immune system. Neoantigens are the basis of the company\u2019s immunotherapy platform. Neoantigens are the target of the immune system. Neoantigens are the basis of the company\u2019s immunotherapy platform. Neoantigens are the target of the immune system. Neoantigens are the basis of the company\u2019s immunotherapy platform. Neoantigens are the target of the immune system. Neoantigens are the basis of the company\u2019s immunotherapy platform. Neoantigens are the target of the immune system. Neoantigens are",
    "similarity_score": 0.4791211187839508
  },
  {
    "token_count": 250,
    "subprompt": "If you have been caught in the legal trap of a domestic violence case then it can snatch your employment, your home and any chance of living a normal life in the future. So contact an efficient domestic violence lawyer Colorado immediately and get the best solution for your problems. For further information please visit out website\n\nNeon Therapeutics Files for $100 Million IPO for Immuno-Oncology Pipeline\n\n\n\nNeon Therapeutics (Proposed Nasdaq: NTGN) has filed for a $100 million initial public offering to fund clinical development of its neoantigen program. Neoantigens result from mutations occurring during tumor growth, are recognized as foreign and differ from native antigens to which the immune system is tolerant. The presence of neoantigens in cancer cells and their absence in normal cells makes them compelling, untapped targets for cancer therapy.\n\n\n\nThe company launched in 2015 with a $55 million Series A investment led by Third Rock Ventures with participation from Clal Biotechnology Industries and Access Industries. The $106 million Series B round in 2017 was led by Partner Fund Management and joined by Third Rock and Access, along with new investors Fidelity, Wellington, Inbio Ventures, Nextech Invest, Pharmstandard",
    "output": ", and others.\n\n\n\nNeon Therapeutics is developing a pipeline of neoantigen-based immunotherapies for the treatment of cancer. The company\u2019s lead product candidate, NCT-502, is a fully human monoclonal antibody that targets the tumor-associated antigen NY-ESO-1. NCT-502 is currently in Phase 1 clinical development for the treatment of multiple myeloma.\n\n\n\nNeon Therapeutics is also developing a pipeline of neoantigen-based immunotherapies for the treatment of cancer. The company\u2019s lead product candidate, NCT-502, is a fully human monoclonal antibody that targets the tumor-associated antigen NY-ESO-1. NCT-502 is currently in Phase 1 clinical development for the treatment of multiple myeloma.\n\n\n\nFor more information, visit the company\u2019s website.\n\nNeon Therapeutics Files for $100 Million IPO for Immuno-Oncology Pipeline\n\n\n\nNeon Therapeutics (Proposed Nasdaq: NTGN) has filed for a $100 million initial public offering to fund clinical development of its neoantigen program. Neoantigens result from mutations occurring during tumor growth, are recognized as foreign and differ from native antigens to which the immune",
    "similarity_score": 0.7671339511871338
  },
  {
    "token_count": 375,
    "subprompt": "If you have been caught in the legal trap of a domestic violence case then it can snatch your employment, your home and any chance of living a normal life in the future. So contact an efficient domestic violence lawyer Colorado immediately and get the best solution for your problems. For further information please visit out website\n\nNeon Therapeutics Files for $100 Million IPO for Immuno-Oncology Pipeline\n\n\n\nNeon Therapeutics (Proposed Nasdaq: NTGN) has filed for a $100 million initial public offering to fund clinical development of its neoantigen program. Neoantigens result from mutations occurring during tumor growth, are recognized as foreign and differ from native antigens to which the immune system is tolerant. The presence of neoantigens in cancer cells and their absence in normal cells makes them compelling, untapped targets for cancer therapy.\n\n\n\nThe company launched in 2015 with a $55 million Series A investment led by Third Rock Ventures with participation from Clal Biotechnology Industries and Access Industries. The $106 million Series B round in 2017 was led by Partner Fund Management and joined by Third Rock and Access, along with new investors Fidelity, Wellington, Inbio Ventures, Nextech Invest, Pharmstandard International, Arrowmark Partners, Hillhouse Capital and Casdin Capital. The IPO will be led by Morgan Stanley, BofA Merrill Lynch and Mizuho Securities.\n\n\n\nNeon is developing a pipeline of personalized neoantigen vaccines and autologous T cell therapies, with an initial focus on melanoma, non-small cell lung cancer (NSCLC) and bladder cancer. The company has collaboration and licensing agreements in place with Vedantra Pharmaceuticals, Apexigen, CRISPR Therapeutics, Bristol-Myers Squibb, Merck, the Netherlands Cancer Institute, the Broad Institute, Dana-Far",
    "output": "ber Cancer Institute, the University of Pennsylvania, the University of California, San Diego, the University of Texas MD Anderson Cancer Center, the University of California, Los Angeles, the University of California, San Francisco, the University of Chicago, the University of California, San Diego, the University of California, San Francisco, the University of California, San Diego, the University of California, San Francisco, the University of California, San Diego, the University of California, San Francisco, the University of California, San Francisco, the University of California, San Francisco, the University of California, San Francisco, the University of California, San Francisco, the University of",
    "similarity_score": 0.49778929352760315
  }
]